ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on…

By V. Fuster, Lars E. Rydén, Davis S. Cannom, H. Crijns, Anne B. Curtis, Kenneth A. Ellenbogen, Jonathan L. Halperin, J. L. Heuzey, G. N. Kay, James E. Lowe and 24 more. European Heart Journal, 2006

1,111 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/3fb3867c27a276dd30440a64b85c9631ea142a90

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Paulus Kirchhof
A. Goette
Ulrich Schotten
S. Verheule
H. Crijns
R. Pisters
C. B. Vos
L. Di Biase

Citations in the corpus

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, unknown): “† The evidence that anticoagulants are effective in reducing thromboembolism in patients with AF is summarized in the joint ACC/AHA/ESC guidelines.(124) † In a series of randomized trials in patients with AF, which included patients with HF, warfarin reduced the risk of stroke by 60–70%.”
Quarterly Focus Issue: Heart Rhythm DisorderClinical Research: Atrial FibrillationProgression From Paroxysmal to Persistent Atrial Fibrillation: Clinical Correlates and Prognosis (2010, background): “n addition, we did not take persistent AF as a separate ntity to evaluate progression to permanent AF because the lassification permanent AF is physician driven and does ot depend on the pathophysiology or clinical characterisics of the arrhythmia and therefore precludes proper assessent of progress”
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. (2011, background): “Reduction of the heart rate might reverse normal pump function, emphasizing that ventricular rate control might not only prevent deterioration of LV function but also restore pump function that is already compromised (188).”
Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. (2012, background): “In patients with CHADS2 score 1, the need for ral anticoagulation is not questionable, but in patients with ow-intermediate risk for stroke (CHADS2 score 1) no onsensus exists on whether patients should receive oral nticoagulation or antiplatelet therapy (18,19).”